TransCode Therapeutics, Inc.
RNAZNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $1.72M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $1.52$15.49
- Volume (live)
- -
- Avg. volume (3M)
- 46.60K
TransCode Therapeutics (RNAZ) Stock Price & Financial Analysis
TransCode Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $1.70 - $1.86 |
|---|---|
| 52-Week High | $15.49 |
| 52-Week Low | $1.52 |
| Open | $1.83 |
| Volume (last close) | 28.97K |
| Average Volume (3M) | 46.60K |
| 50-Day MA | $2.27 |
|---|---|
| 200-Day MA | $6.50 |
| 1-Year Change | −88.18% |
| Market Cap | 1.72M |
|---|---|
| Shares Outstanding | 957.19K |
| Price to Book (P/B) | 0.01 |
| EV/EBITDA | 0.19 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
TransCode Therapeutics at a Glance
As of the Oct 16, 2026 close, TransCode Therapeutics (RNAZ) has a market capitalization of $1.72M.
As of its latest reported balance sheet, it holds $8.38M in cash and securities against $652.41K of debt, a net cash position of $7.73M.
TransCode Therapeutics does not currently pay a dividend.
The share price is down 88.2% over the past year. At $1.70 (the Oct 16, 2026 close) it sits near the bottom of its 52-week range of $1.52 to $15.49, below its 200-day moving average of $6.50.
Frequently Asked Questions About TransCode Therapeutics
What is the current stock price for RNAZ?
As of the Oct 16, 2026 close, RNAZ stock trades at $1.70. The 52-week range is $1.52–$15.49, with a day range of $1.70–$1.86.
What is the P/E ratio for RNAZ?
The P/E ratio (Price-to-Earnings) for RNAZ is shown in the Key Statistics section. This valuation metric helps compare TransCode Therapeutics, Inc. to industry peers.
Does RNAZ pay dividends?
TransCode Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for RNAZ?
Analyst ratings and recommendations for RNAZ are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.
What is the market cap of RNAZ?
As of the Oct 16, 2026 close, TransCode Therapeutics's market capitalization is $1.6M, classifying it as a micro-cap company. TransCode Therapeutics operates in the Healthcare sector within the Biotechnology industry.